中国药物评价2025，Vol.42Issue(4)：295-299,5.
基于网络药理学和分子对接探讨丙戊酸治疗乳腺癌的作用机制
The Mechanism of Action of Valproic Acid in the Treatment of Breast Cancer A Study Based on Network Pharmacology and Molecular Docking
摘要
Abstract
Objective:To explore the mechanism of action of valproic acid(VPA)in the treatment of breast cancer based on net-work pharmacology and molecular docking.Methods:VPA-related targets were retrieved using three online databases,namely Gen-eCards,DrugBank,and PharmGKB.Gene targets related to breast cancer were screened based on the GeneCards and PharmGKB databases,and the intersection was taken by Venny 2.1.0.The relevant data were imported into the STRING database to construct the PPI network.The Cytoscape 3.9.1 software was used to visualize it and screen out the core targets.The intersection targets were analyzed for functional enrichment through GO and KEGG,and the core targets were verified through molecular docking.Results:Network pharmacology screened out 209 intersection targets between VPA and breast cancer,including 8 core targets.The related signaling pathways enriched included cancer-related pathways,PI3K-Akt signaling pathway,FoxO signaling pathway,p53 signaling pathway,and platinum-based drug resistance,etc.Conclusion:The potential targets of VPA's effect on breast cancer include MAPK3,ESR1,CREBBP,HDAC1,HIF1A,and TP53.The mechanism of action may be related to the PI3K-Akt signaling pathway,proteoglycan in cancer,FoxO signaling pathway,p53 signaling pathway,and platinum-based drug resistance,etc.Studies have shown that VPA can regulate the body's immunity through multiple components,multiple targets and multiple pathways.关键词
丙戊酸/乳腺癌/作用机制/网络药理学/分子对接Key words
Valproic acid/Breast cancer/Mechanism of action/Network pharmacology/Molecular docking分类
医药卫生引用本文复制引用
鲁赛娟,王国徽,张函舒,李兴德,毛盼盼,宋沧桑..基于网络药理学和分子对接探讨丙戊酸治疗乳腺癌的作用机制[J].中国药物评价,2025,42(4):295-299,5.基金项目
云南省卫生健康委医学领军人才培养计划(L-2018012) （L-2018012）
云南省临床药学中心建设项目 （）
基金项目1:昆明市卫生科技人才培养项目——医学科技领军人才培养计划[2023-SW(领军)-04] （领军）
昆明市卫生科技人才培养项目医学科技学科后备人才培养计划[2023-SW(后备)-11] （后备）
昆明医科大学研究生教育创新基金(2025S333) （2025S333）
